Researchers using nano technology believe they are making progress in the battle against Alzheimer’s Disease, according to the new issue of NanoBiotech News.
A team from Northwestern University, the University of Southern California in Los Angeles, and Acumen Pharmaceuticals have discovered as much as 70 times the number of small proteins called ADDLs in the brains of Alzheimer’s patients, the newsletter reported.
These so-called neurotoxic peptide assemblies “may be responsible for the memory loss” that affects Alzheimer’s patients. The researchers plan to develop diagnostic methods employing nanoparticles to detect the ADDLS and also to develop drugs to prevent the onset of Alzheimer’s.
“The fact that these researchers are immediately turning to
nanobiotechnology as the next step in their R&D process – on the heels of such a significant discovery – is yet another clear indication that nanobiotechnology is now a widely accepted, and sought after scientific approach to solving some of the most complex human health problems,” said Lynn Yoffee, associate publisher of NanoBiotech News.
The weekly newsletter is published by Atlanta-based National Health Information.
For information about the newsletter, visit: www.nanobiotechnews.com
